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ready to drink?
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Jan J. Cornelissen1 1ERASMUS UNIVERSITY MEDICAL CENTER
In this issue of Blood, Walter et al describe the impact of minimal residual disease
(MRD) as measured by multicolor flow cytometry (MCF) on relapse,
progression-free survival (PFS), and overall survival (OS) in acute myeloid
leukemia (AML) patients who received an allogeneic hematopoietic stem cell
transplantation (alloHSCT).1
S ince the concept of MRD wasintroduced in the early 1980s, it has
only been gradually introduced into clinical
practice.2 The most important examples
are the current standard use of quantitative
polymerase chain reaction (qPCR) in patients
with chronic myeloid leukemia3 and the
use of flow cytometry and qPCR in acute
lymphoblastic leukemia.4 Apart from the use
of PCR in acute promyelocytic leukemia,
MRD is currently not routinely monitored in
AML patients. Walter et al report that
MRD strongly impacts on PFS and OS
in alloHSCT recipients with AML, and
in a similar degree in first and second
remission.1 That effect became evident
as from a cutoff level of 0.1%, without
significantly changing in patients with
increasing levels of MRD.
Although MRD as an innovative concept
was first suggested in AML, it took almost 3
decades for MRD to mature in AML.5 An
important question to be addressed today is
whether recent studies, including the present
study from Seattle, urge us to adapt our
transplant policy. The choice of postremission
treatment in AML is currently under intense
debate (see figure). Although alloHSCT
provides the strongest antileukemic
treatment, the benefit can be compromised by
nonrelapse mortality (NRM). Therefore,
a careful assessment of the most important
variables affecting relapse and NRM should
be included in the workup of transplant
recipients nowadays. A recent review by the
European Leukemia Net (ELN) AML
working group6 described that approach in
detail for AML transplant recipients, taking
into account on one hand the parameters
predicting relapse and on the other hand
parameters predicting NRM in a time-
dependent fashion (see figure). The ELN
recommended to aim for a disease-free survival
(DFS) benefit by alloHSCT of at least 10% for
the individual patient as compared with a non-
alloHSCT approach. Such a DFS benefit may
be achieved in AML intermediate- and poor-
risk patients, provided that the risk of NRM
does not exceed 25% and 35%, respectively.
Good-risk AML patients, as defined by
cytogenetic and molecular hallmarks,6 do not
currently receive an alloHSCT as part of first-
line treatment because the DFS benefit is
limited and those patients may effectively be
rescued upon relapse.7
Should intermediate-risk patients without
MRD after induction chemotherapy be
considered as good-risk patients? The study
by Walter et al1 and by other investigators8,9
may seem to suggest this, but more
information is needed before adapting
a transplant policy. First, prospective studies
reporting outcome of AML intermediate-risk
MRD-negative patients who do not proceed
to alloHSCT because of MRD negativity
would be needed. Prospective studies,
addressing this particular issue have not been
reported yet, and the question whether
Time frame and parameters for decision making prior to allogeneic hematopoietic stem cell transplantation (HSCT) in
AML. HCT-CI, hematopoietic stem cell transplantation comorbidity index; EBMT, European Group for Blood and
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alloHSCT can be withheld in that subgroup
is still open but urgent. Especially because
of a lower rescue rate with reinduction
chemotherapy in intermediate-risk patients in
general.10 Second, methods of MCF vary
among different studies. Some of the methods
apply MRD monitoring by first establishing
a leukemia-associated phenotype (LAP) at
diagnosis.8,9 The present study applied a
different approach by defining MRD by
any deviation of the normal pattern of
regenerating or normal marrow, which
circumvents the need for a LAP and also
circumvents the problem of a phenotypic shift
that may occur during chemotherapy. This
approach may seem very attractive, but from
a technical point of view, the method is
challenging and so far is only being used by a
very limited number of centers. Therefore, the
MCF method applied in the present study
would need validation in prospective studies
on a broader scale. Moreover, such confirmation
is also needed to be able to quantitatively
weigh all relevant prognostic markers prior to
alloHSCT within a single, large study, including
parameters predicting for NRM.
MRD-positivity in the present study
appeared to be associated with a 3-year OS
of 32% and 44% in CR1 and CR2 patients,
respectively. Although the relapse rate after
alloHSCT was relatively high in those patients,
the allogeneic graft-vs-leukemia (GVL) effect
was suggested not to differ between MRD-
negative and MRD-positive patients. Of
interest, as a reflection of GVL activity, the
present study showed a strong reduction of
relapse (hazard ratio: 0.46 (0.24-0.88); P5 .02)
in patients with chronic graft-vs-host disease,
which was similarly exerted in patients with or
without MRD. Therefore, the higher relapse
rate in MRD-positive patients does not
indicate that GVL was absent, but rather
suggests that the allogeneic GVL effect would
need to be exploited more effectively. Several
approaches may be developed into that
direction, but monitoring of MRD at regular
intervals after alloHSCT with subsequent
adaptation of the immunosuppressive regimen
and/or donor lymphocyte infusion may be one
of them. In addition, intermediate-risk patients
who are MRD-positive after induction and
consolidation chemotherapy may be candidates
for an alloHSCT using stem cells from
alternative donors, which type of transplants is
currently not routinely offered to those patients
if MRD information is lacking.
Collectively, the present study1 and other
studies in AML8,9 strongly suggest that
the net effect of the combination of an
anthracycline and cytarabine in AML
currently needs to be evaluated by both flow
cytometry and microscopic evaluation to
obtain optimal information regarding the risk
of relapse. A change of transplant policy
seems premature in intermediate-risk patients
who become MRD-negative after induction
chemotherapy and further prospective studies
would be needed. Finally, despite the
adverse prognostic impact of MRD-positivity,
these patients do benefit from alloHSCT,
which, therefore, should be pursued, even
with alternative donors, and preferably
be optimized by exploiting GVL more
effectively. Therefore, after 30 years of
MRD maturation in AML, we may now
begin to sip of this extraordinary wine.
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Tregs, HSCT, and acute GVHD:
up close and personal
-----------------------------------------------------------------------------------------------------
John Koreth1 and Jerome Ritz1 1DANA-FARBER CANCER INSTITUTE
In this issue of Blood, Dong et al present a unique detailed view of human
regulatory T-cell (Treg) diversity in homeostatic and pathological states after
allogeneic hematopoietic stem cell transplantation (alloHSCT).1
A lloHSCT provides curative graft-versus-tumor potential for patients with
hematologic malignancies. However, donor
effector immune responses to allogeneic
(donor/recipient polymorphic) and
autologous (donor/recipient nonpolymorphic)
antigens also underlie acute and chronic
graft-versus-host disease (GVHD), the major
toxicities of this therapeutic approach.
CD41CD251Foxp31 regulatory
T lymphocytes comprise ;5% to 10% of
circulating CD41 T cells and migrate to
inflammatory sites to control innate and
adaptive immune responses, especially those
due to effector lymphocytes of helper T (Th)
subsets: Th1, Th2, Th17, and follicular Th
cells (reviewed by Ohkura et al2). Tregs play
a critical role in the prevention of
autoimmunity and several studies have
suggested that Tregs also play a central role
in the establishment and maintenance of
immune tolerance after alloHSCT.
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